Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: J Autoimmun. 2020 Oct 13;115:102549. doi: 10.1016/j.jaut.2020.102549

Figure 1b.

Figure 1b.

Panel A shows the number of T lymphocytes (CD3+) and panel B the number of B lymphocytes (CD19+) at baseline and two and six weeks after oral therapy with fingolimod. In Panel C, data are expressed as percentage of pre-treatment levels. Control mice received saline. Groups of four female mice, aged 12 weeks. The experiment was repeated twice with similar results, with a total of nine treated and nine control mice in these depletion experiments.